Phase 2b Trial of a Na <sub>V</sub> 1.8 Inhibitor for Acute Pain
N
Neil Singla
(Latigo Biotherapeutics, Thousand Oaks, CA)
N
Nathaniel P. Katz
(Ein Sof Innovation, Boston)
B
Ben Vaughn
(Latigo Biotherapeutics, Thousand Oaks, CA)
T
Timothy Rogier
(Latigo Biotherapeutics, Thousand Oaks, CA)
T
Todd Bertoch
(CenExel, Salt Lake City)
H
Harold Minkowitz
(Evolution Research Group Research, New Providence, NJ)
M
Mallory Loflin
(Latigo Biotherapeutics, Thousand Oaks, CA)
Article Details
Journal
New England Journal of Medicine
Volume / Issue
Vol. 395, Issue 5
Published
July 30, 2026
Pages
454-464
ISSN
0028-4793
Publisher
Massachusetts Medical Society
Journal Info
New England Journal of Medicine
Massachusetts Medical Society
ISSN: 0028-4793 Social Sciences
Authors (7)
N
Neil Singla
Latigo Biotherapeutics, Thousand Oaks, CA
N
Nathaniel P. Katz
Ein Sof Innovation, Boston
B
Ben Vaughn
Latigo Biotherapeutics, Thousand Oaks, CA
T
Timothy Rogier
Latigo Biotherapeutics, Thousand Oaks, CA
T
Todd Bertoch
CenExel, Salt Lake City
H
Harold Minkowitz
Evolution Research Group Research, New Providence, NJ
M
Mallory Loflin
Latigo Biotherapeutics, Thousand Oaks, CA
Related Articles from this Journal
Doctor’s Dirty Little Secret — The Cost of Silence
Tara Khan
Aug 2026
10.1056/nejmp2515506
Obstructive Hypertrophic Cardiomyopathy
Julian-Kai Nishizono, Marohito Nakata
Aug 2026
10.1056/nejmicm2603868
T-Cell Engager–Mediated HLA Antibody Depletion before Kidney Transplantation
Martina Schatzl, Katharina A. Mayer et al.
Jul 2026
10.1056/nejmc2603853
Products That Pose Health Risks — Can Litigation Protect Us When Government Fails?
Jerry Avorn
Jul 2026
10.1056/nejmp2604841
Precision Intensification in Metastatic Prostate Cancer
Rana R. McKay
Jul 2026
10.1056/nejme2605582